186 related articles for article (PubMed ID: 38672511)
1. Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.
Navals P; Rangaswamy AMM; Kasyanchyk P; Berezovski MV; Keillor JW
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672511
[TBL] [Abstract][Full Text] [Related]
2. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors.
McNeil NMR; Gates EWJ; Firoozi N; Cundy NJ; Leccese J; Eisinga S; Tyndall JDA; Adhikary G; Eckert RL; Keillor JW
Eur J Med Chem; 2022 Mar; 232():114172. PubMed ID: 35158154
[TBL] [Abstract][Full Text] [Related]
4. Nucleotide binding kinetics and conformational change analysis of tissue transglutaminase with switchSENSE.
Staffler R; Pasternack R; Hils M; Kaiser W; Möller FM
Anal Biochem; 2020 Sep; 605():113719. PubMed ID: 32697952
[TBL] [Abstract][Full Text] [Related]
5. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
Jasim MH; Rathbone DL
J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.
Akbar A; McNeil NMR; Albert MR; Ta V; Adhikary G; Bourgeois K; Eckert RL; Keillor JW
J Med Chem; 2017 Sep; 60(18):7910-7927. PubMed ID: 28858494
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Siegel M; Khosla C
Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 undergoes a large conformational change upon activation.
Pinkas DM; Strop P; Brunger AT; Khosla C
PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
10. The Outside-In Journey of Tissue Transglutaminase in Cancer.
Sima LE; Matei D; Condello S
Cells; 2022 May; 11(11):. PubMed ID: 35681474
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
Valdivia A; Vagadia PP; Guo G; O'Brien E; Matei D; Schiltz GE
J Med Chem; 2023 Jul; 66(14):9445-9465. PubMed ID: 37449845
[TBL] [Abstract][Full Text] [Related]
13. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells.
Caron NS; Munsie LN; Keillor JW; Truant R
PLoS One; 2012; 7(8):e44159. PubMed ID: 22952912
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten.
Feriotto G; Calza R; Bergamini CM; Griffin M; Wang Z; Beninati S; Ferretti V; Marzola E; Guerrini R; Pagnoni A; Cavazzini A; Casciano F; Mischiati C
Amino Acids; 2017 Mar; 49(3):551-565. PubMed ID: 27699491
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
16. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
17. Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.
Kanchan K; Fuxreiter M; Fésüs L
Cell Mol Life Sci; 2015 Aug; 72(16):3009-35. PubMed ID: 25943306
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site.
Jang TH; Lee DS; Choi K; Jeong EM; Kim IG; Kim YW; Chun JN; Jeon JH; Park HH
PLoS One; 2014; 9(9):e107005. PubMed ID: 25192068
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 has higher affinity for relaxed than for stretched fibronectin fibers.
Selcuk K; Leitner A; Braun L; Le Blanc F; Pacak P; Pot S; Vogel V
Matrix Biol; 2024 Jan; 125():113-132. PubMed ID: 38135164
[TBL] [Abstract][Full Text] [Related]
20. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
